MARKET

CRDL

CRDL

Cardiol Therapeu
NASDAQ
1.040
+0.020
+1.96%
Closed 17:37 02/17 EST
OPEN
1.030
PREV CLOSE
1.040
HIGH
1.060
LOW
1.010
VOLUME
188.02K
TURNOVER
0
52 WEEK HIGH
1.590
52 WEEK LOW
0.7709
MARKET CAP
116.15M
P/E (TTM)
-3.4414
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRDL last week (0209-0213)?
Weekly Report · 1d ago
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Benzinga · 02/10 18:00
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and Centene (CNC)
TipRanks · 02/10 16:10
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure
TipRanks · 02/10 12:58
Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology
Benzinga · 02/10 12:30
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx in Acute Myocarditis
Reuters · 02/10 12:28
Cardiol Therapeutics veröffentlicht positive Phase-II-Studienergebnisse zu CardiolRx bei akuter Myokarditis
Reuters · 02/10 12:28
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile · 02/10 12:27
More
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Webull offers Cardiol Therapeutics Inc stock information, including NASDAQ: CRDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDL stock methods without spending real money on the virtual paper trading platform.